Accelrys Completes Merger with Symyx; Will Cut up to 15 Percent of Combined Workforce | GenomeWeb

Accelrys this week completed its all-stock merger with Symyx Technologies, forming a scientific informatics company with more than 1,350 customers and annual revenues of approximately $170 million.

The new firm will do business under the name of Accelrys and will trade on the Nasdaq stock exchange under the symbol ACCL.

In documents filed with the US Securities and Exchange Commission after the merger, Accelrys disclosed that it plans to lay off approximately 80 employees, or between 10 percent and 15 percent of new entity's combined workforce.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In Nucleic Acids Research this week: tool to discover copy number variants, single-nucleus RNA sequencing study of myoblasts, and more.

A study of Tasmanian devil genomes suggests they are evolving resistance to devil facial tumor disease.

Theranos has withdrawn its request for emergency clearance of a Zika virus blood test, according to the Wall Street Journal.

An assistant professor who was fired from Mount Sinai School of Medicine has allegedly shot the school's dean, the New York Times reports.